A novel use for the biodegradable temporizing matrix.
Biodegradable temporizing matrix
Skin graft
Tendon tethering
Journal
European journal of plastic surgery
ISSN: 0930-343X
Titre abrégé: Eur J Plast Surg
Pays: Germany
ID NLM: 8700891
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
11
2021
accepted:
19
04
2022
pubmed:
1
6
2022
medline:
1
6
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Biodegradable Temporising Matrix (BTM), a skin substitute, has been recently developed as a novel adjunct to the plastic surgeon's reconstructive repertoire. Its use has been described in literature in a variety of settings and complex wounds, including those that previously would have been described as "non-graftable", with favourable outcomes. We present the case of a patient with a wound to the right foot and ankle following extravasation injury. Following surgical debridement, this injury was managed with BTM, which allowed granulation and production of a "neo-dermis". A split-thickness skin graft was subsequently applied. The characteristics of the BTM allowed the resulting skin graft and scar to be pliable, avoiding tendon tethering and joint contracture. To the authors' knowledge, this skin substitute has not been reported in a wound of this aetiology before. It is our hope that this report will provide evidence to colleagues that this is a valuable adjunct that may be used in complex wounds. Level of evidence: Level V, therapeutic study. The online version contains supplementary material available at 10.1007/s00238-022-01964-z.
Identifiants
pubmed: 35637749
doi: 10.1007/s00238-022-01964-z
pii: 1964
pmc: PMC9134145
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1015-1020Informations de copyright
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.
Déclaration de conflit d'intérêts
Conflict of interestThe supervising author (G. J. Offer) owns shares in PolyNovo, the company which produces the product described in this article, NovoSorb© BTM. Stephen R. Frost and Avinash Deodhar declare no competing interests.